{
    "nct_id": "NCT00982202",
    "title": "Pioglitazone in Alzheimer Disease Progression",
    "status": "COMPLETED",
    "last_update_time": "2009-09-22",
    "description_brief": "This study was designed to assess the safety and tolerability of pioglitazone, an approved drug for type 2 diabetes, in non diabetic patients with Alzheimer's disease. It was also designed to generate preliminary information on whether pioglitazone might slow progression of Alzheimer's disease.",
    "description_detailed": "Inflammatory processes are important in the progressive loss of memory and thinking skills in Alzheimer's disease (AD). Laboratory studies show that drugs that bind to a protein known as \"Peroxisome Proliferator Activated Receptor-gamma (PPARgamma)\" act to reduce inflammatory responses in brain cells known as microglia when they are exposed to amyloid peptide, a major part of AD pathology. Therefore, drugs that activate PPARgamma have great potential for reducing the progression of AD. Pioglitazone (PGZ) activates PPARgamma and has shown favorable clinical experiences and safety profiles in patients with diabetes. This is a pilot study to determine the safety and tolerability of PGZ in patients with AD. Another goal of the study is to assess how clinical measures of cognition, daily function, and behavior might respond to PGZ treatment.",
    "phase": [
        "PHASE2"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "TREATMENT",
    "results": null,
    "target_category": "disease-targeted small molecule",
    "drug": [
        "pioglitazone (Actos) \u2014 a thiazolidinedione, PPAR\u03b3 agonist, small-molecule insulin-sensitizer repurposed for AD trials. \ue200cite\ue202turn0search1\ue202turn0search12\ue201"
    ],
    "placebo": [
        "matching placebo (trial was double\u2011blind, placebo\u2011controlled). \ue200cite\ue202turn0search0\ue202turn0search4\ue201"
    ],
    "explanation_target": [
        "Reason: The trial tested pioglitazone, a small\u2011molecule thiazolidinedione that acts as a PPAR\u03b3 agonist and has anti\u2011inflammatory/metabolic effects thought to affect Alzheimer pathology (amyloid/tau/inflammation). The protocol explicitly sought preliminary evidence that pioglitazone might slow AD progression (disease\u2011modifying intent). \ue200cite\ue202turn0search4\ue202turn0search1\ue201",
        "Act (key details & sources): The study description (NCT00982202) states it was designed to assess safety/tolerability of pioglitazone in non\u2011diabetic AD patients and to generate preliminary information on slowing disease progression. A published randomized pilot trial reports pioglitazone (titrated to 45 mg daily) vs matching placebo, found it generally tolerated but did not show significant efficacy in that small study. \ue200cite\ue202turn0search4\ue202turn0search0\ue201",
        "Act (drug identity): Pioglitazone is an FDA\u2011approved small\u2011molecule antidiabetic (thiazolidinedione) marketed as Actos; its mechanism involves activation of the nuclear receptor PPAR\u03b3 and modulation of inflammatory and metabolic pathways relevant to AD in preclinical and some clinical reports. \ue200cite\ue202turn0search12\ue202turn0search3\ue202turn0search5\ue201",
        "Reflect: Classification as 'disease\u2011targeted small molecule' fits because (1) the agent is a small molecule (not a biologic), (2) the trial goal was to test impact on disease progression (not solely symptomatic cognitive enhancement or neuropsychiatric symptom relief), and (3) the proposed mechanism targets AD\u2011relevant biology (inflammation/amyloid/tau pathways). Some ambiguity exists because pioglitazone primarily treats metabolic disease and can have symptomatic metabolic/cognitive effects, but the trial intent and preclinical rationale were disease\u2011modifying. \ue200cite\ue202turn0search4\ue202turn0search6\ue201"
    ],
    "agent_type": "J) Metabolism and Bioenergetics",
    "explanation_agent": [
        "Reason: Pioglitazone is a thiazolidinedione small molecule whose primary molecular target is the nuclear receptor PPAR\u03b3, a regulator of glucose/lipid metabolism and cellular bioenergetics; its repurposing in AD is driven by metabolic/insulin\u2011sensitizing effects and downstream modulation of inflammatory and clearance pathways. \ue200cite\ue202turn0search5\ue202turn0search4\ue201",
        "Act: Key trial and drug details support a metabolism/bioenergetics classification \u2014 the NIA\u2011sponsored Phase\u20112 trial NCT00982202 tested pioglitazone (Actos) titrated to 45 mg vs placebo in non\u2011diabetic AD patients to assess safety/tolerability and possible slowing of disease progression; the published randomized pilot RCT (titrated to 45 mg) found tolerability but no significant efficacy in that small study. Pioglitazone\u2019s mechanism as a PPAR\u03b3 agonist and its metabolic/anti\u2011inflammatory actions are documented in preclinical and clinical reports. \ue200cite\ue202turn0search2\ue202turn0search0\ue202turn0search6\ue201",
        "Reflect: Although pioglitazone also has clear anti\u2011inflammatory effects on microglia (which maps to CADRO F), its primary molecular target and canonical role are in metabolic regulation (PPAR\u03b3 control of glucose and lipid metabolism). Given CADRO\u2019s categories, the most specific fit is J) Metabolism and Bioenergetics; if one emphasized the anti\u2011inflammatory mechanism instead, F) Inflammation would be a defensible secondary classification, but the explicit drug target (PPAR\u03b3) points to metabolic/bioenergetic pathways. \ue200cite\ue202turn0search5\ue202turn0search4\ue201",
        "Web search results (key sources used):",
        "- PubMed: randomized pilot trial of pioglitazone in AD (safety/tolerability; NCT00982202). \ue200cite\ue202turn0search0\ue201",
        "- ClinicalTrials/NCT00982202 trial record (Pioglitazone in Alzheimer Disease Progression). \ue200cite\ue202turn0search2\ue201",
        "- Journal of Neuroinflammation: pioglitazone neuroprotective/anti\u2011inflammatory mechanisms. \ue200cite\ue202turn0search4\ue201",
        "- Frontiers review reassessing pioglitazone for AD (mechanisms: metabolic and immune effects via PPAR\u03b3). \ue200cite\ue202turn0search5\ue201",
        "Final classification: J) Metabolism and Bioenergetics \u2014 Pioglitazone\u2019s primary molecular target (PPAR\u03b3) and its insulin\u2011sensitizing/metabolic actions make the Metabolism/Bioenergetics CADRO category the best match; anti\u2011inflammatory actions are recognized as a complementary mechanism (CADRO F)."
    ]
}